Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb;9(2):77-86.
doi: 10.1002/psp4.12480. Epub 2020 Jan 11.

Estimation of an Appropriate Dose of Trazodone for Pediatric Insomnia and the Potential for a Trazodone-Atomoxetine Interaction

Laura Oggianu  1 , Alice B Ke  2 , Manoranjenni Chetty  2 , Rossella Picollo  1 , Vanessa Petrucci  1 , Fabrizio Calisti  1 , Fabio Garofolo  1 , Serena Tongiani  1
Affiliations

Estimation of an Appropriate Dose of Trazodone for Pediatric Insomnia and the Potential for a Trazodone-Atomoxetine Interaction

Laura Oggianu et al. CPT Pharmacometrics Syst Pharmacol. 2020 Feb.

Abstract

There is a paucity of clinical trials for the treatment of pediatric insomnia. This study was designed to predict the doses of trazodone to guide dosing in a clinical trial for pediatric insomnia using physiologically-based pharmacokinetic (PBPK) modeling. Data on the pharmacokinetics of trazodone in children are currently lacking. The interaction potential between trazodone and atomoxetine was also predicted. Doses predicted in the following age groups, with exposures corresponding to adult dosages of 30, 75, and 150 mg once a day (q.d.), respectively, were: (i) 2- to 6-year-old group, doses of 0.35, 0.8, and 1.6 mg/kg q.d.; (ii) >6- to 12-year-old group, doses of 0.4, 1.0, and 1.9 mg/kg q.d.; (iii) >12- to 17-year-old group, doses of 0.4, 1.1, and 2.1 mg/kg q.d. An interaction between trazodone and atomoxetine was predicted to be unlikely. Clinical trials based on the aforementioned predicted dosing are currently in progress, and pharmacokinetic data obtained will enable further refinement of the PBPK models.

PubMed Disclaimer

Conflict of interest statement

L.O., R.P., V.P., F.C., F.G. and S.T. are employees of Angelini S.p.A. A.B.K. and M.C. are employees of Certara UK, Simcyp Division.

Figures

Figure 1
Figure 1
Summary of physiologically‐based pharmacokinetic (PBPK) strategy for predicting the exposure of trazodone in children. CYP, cytochrome P450; DDI, drug–drug interaction; fmCYP3A4, CYP3A4 contribution.
Figure 2
Figure 2
Predicted (black line represents mean, and gray lines represent individual trials) and observed (circles; (a–d) 31, (e) 32, (f) 25, 32) trazodone plasma concentration profiles following the administration of different doses and formulations. ER, extended release; IR, immediate release; q.d., once a day; TID, three times a day.
Figure 3
Figure 3
Predicted median total plasma concentration‐time profiles of trazodone following the respective predicted final doses in 2–6, >6–12, and > 12–17 year olds. These were based on matching the adult Cmax following 30 mg IR q.d. for 7 days (a,b), 75 mg IR q.d. for 7 days (c,d), and 150 mg IR q.d. for 7 days (e,f). h, hour; yrs, years.
See this image and copyright information in PMC

References

    1. Souders, M.C. et al Sleep behaviors and sleep quality in children with autism spectrum disorders. Sleep 32, 1566–1578 (2009). - PMC - PubMed
    1. Angriman, M. , Caravale, B. , Novelli, L. , Ferri, R. & Bruni, O. Sleep in children with neurodevelopmental disabilities. Neuropediatrics 46, 199–210 (2015). - PubMed
    1. Hvolby, A. , Jørgensen, J. & Bilenberg, N. Actigraphic and parental reports of sleep difficulties in children with attention‐deficit/hyperactivity disorder. Arch. Pediatr. Adolesc. Med. 162, 323–329 (2008). - PubMed
    1. Miano, S. & Ferri, R. Epidemiology and management of insomnia in children with autistic spectrum disorders. Paediatr. Drugs 12, 75–84 (2010). - PubMed
    1. Blackmer, A.B. & Feinstein, J.A. Management of sleep disorders in children with neurodevelopmental disorders: a review. Pharmacotherapy 36, 84–98 (2016). - PubMed

Publication types

MeSH terms

Substances